translation agency

NLM AIDSLINE
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA [see comments]
Rizzardi GP; De Boer RJ; Hoover S; Tambussi G; Chapuis A; Halkic N; Bart
June 30, 2000
dine/ADMINISTRATION & DOSAGE/PHARMACOLOGY/THERAPEUTIC USE J Clin Invest.

JOURNAL ARTICLE MULTICENTER STUDY Adult Anti-HIV Agents/*ADMINISTRATION & DOSAGE/PHARMACOLOGY/THERAPEUTIC USE Cohort Studies CD4 Lymphocyte Count/DRUG EFFECTS CD4-Positive T-Lymphocytes/PATHOLOGY Dideoxynucleosides/ADMINISTRATION & DOSAGE/PHARMACOLOGY/ THERAPEUTIC USE Human HIV Infections/*DRUG THERAPY/IMMUNOLOGY/VIROLOGY HIV Protease Inhibitors/ADMINISTRATION & DOSAGE/PHARMACOLOGY/ THERAPEUTIC USE HIV-1/*ISOLATION & PURIF HIV-1 Reverse Transcriptase/ANTAGONISTS & INHIB Lamivudine/ADMINISTRATION & DOSAGE/PHARMACOLOGY/THERAPEUTIC USE Lymph Nodes/VIROLOGY Nelfinavir/ADMINISTRATION & DOSAGE/PHARMACOLOGY/THERAPEUTIC USE Reverse Transcriptase Inhibitors/ADMINISTRATION & DOSAGE/ PHARMACOLOGY/THERAPEUTIC USE RNA, Viral/*BLOOD Saquinavir/ADMINISTRATION & DOSAGE/PHARMACOLOGY/THERAPEUTIC USE Stavudine/ADMINISTRATION & DOSAGE/PHARMACOLOGY/THERAPEUTIC USE Sulfonamides/ADMINISTRATION & DOSAGE/PHARMACOLOGY/THERAPEUTIC USE Support, Non-U.S. Gov't Time Factors *Viral Load Viremia/*DRUG THERAPY Zidovudine/ADMINISTRATION & DOSAGE/PHARMACOLOGY/THERAPEUTIC USE J Clin Invest. 2000 Mar;105(6):777-82. Unique Identifier : AIDSLINE MED/20193683

www.aegis.org